CD63 and urinary bladder carcinoma: Since this portion of EVs would less likely add clinically relevant diagnostic values for assessing the risks of bladder cancer, we excluded the use of DTT to remove THP from urine in the CD63-based microchip ELISA for analyzing urinary EVs derived from bladder cancer patients.